S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(-0.01%) $0.926
USD/NOK
(-0.07%) $10.83
USD/GBP
(-0.13%) $0.791
USD/RUB
(-0.21%) $92.38

Realtime updates for NOXXON Pharma NV [ALNOX.PA]

Exchange: EURONEXT Industry: Biotechnology
Last Updated31 Dec 1970 @ 19:00

0.00% 0.0410


Warning: Attempt to read property "price" on null in /home/getagraph/public_html/signalbox.php on line 2

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...

Stats
Today's Volume 10.21M
Average Volume 4.35M
Market Cap 0.00
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -0.187
ATR14 €0 (0.00%)

Warning: Attempt to read property "price" on null in /home/getagraph/public_html/stock.php on line 498

NOXXON Pharma NV Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NOXXON Pharma NV Financials

Annual 2021
Revenue: €0.00
Gross Profit: €0.00 (0.00 %)
EPS: €-45.99
Q2 2019
Revenue: €0.00
Gross Profit: €-257 250 (0.00 %)
EPS: €-1.929
Q1 2019
Revenue: €0.00
Gross Profit: €-257 250 (0.00 %)
EPS: €-1.929
Q1 2019
Revenue: €0.00
Gross Profit: €-257 250 (0.00 %)
EPS: €-1.929

Financial Reports:

No articles found.

NOXXON Pharma NV

NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators